Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Liabilities and Shareholders Equity (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $638.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 81.29% year-over-year to $638.5 million, compared with a TTM value of $1.4 billion through Dec 2025, up 23.01%, and an annual FY2025 reading of $638.5 million, up 81.29% over the prior year.
  • Liabilities and Shareholders Equity was $638.5 million for Q4 2025 at Wave Life Sciences, up from $241.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $638.5 million in Q4 2025 and bottomed at $146.4 million in Q4 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $255.6 million, with a median of $232.6 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 35.33% in 2021, then soared 87.82% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $207.0 million in 2021, then decreased by 29.28% to $146.4 million in 2022, then skyrocketed by 87.82% to $274.9 million in 2023, then increased by 28.1% to $352.2 million in 2024, then surged by 81.29% to $638.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for WVE at $638.5 million in Q4 2025, $241.4 million in Q3 2025, and $252.4 million in Q2 2025.